Literature DB >> 23419631

Medication overuse headaches.

Bernard M Abrams1.   

Abstract

“An ounce of prevention is worth a pound of cure” in the management of MOH. Prevention of transformation of primary headache types to their chronic counterparts is necessary to prevent this most troubling transformation. Strict attention to what patients are telling you (and often times not telling you) about their episodic headaches will enable pharmacologic and nonpharmacologic measures to avoid that transformation to chronic daily headache, so often associated with MOH. Once MOH becomes manifest, withdrawal of the overused drug is mandatory; otherwise experience tells us the pattern of overuse will only be perpetuated and no measure will help alleviate the headache. At the same time, as detoxification takes place, measures to ensure that relapse will not take place should begin. These efforts include prophylactic pharmacologic measures as well as psychological support, education, and surveillance to prevent relapses. The rate of relapse is unfortunately high, but these general and specific measures enumerated above will add greatly to the chances of success.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419631     DOI: 10.1016/j.mcna.2012.12.007

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

Review 1.  Supraorbital and supratrochlear stimulation for trigeminal autonomic cephalalgias.

Authors:  Julien Vaisman; Edrick Lopez; Nicholas K Muraoka
Journal:  Curr Pain Headache Rep       Date:  2014-04

2.  Analysis of risk factors for medication-overuse headache relapse: a clinic-based study in China.

Authors:  Zhihui Yan; Yuan Chen; Chunfu Chen; Congcong Li; Xiaojun Diao
Journal:  BMC Neurol       Date:  2015-09-17       Impact factor: 2.474

3.  Heroin-induced headache in female heroin addicts.

Authors:  Li Li; Shengyuan Yu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.